Alzamend Neuro is trading 6.86% down at $1.49, likely under pressure from dilution concerns tied to an August 21 registration filing.
- The filing covers securities offered by selling stockholders.
- The decline extends weakness from the August 25 close of $1.60.
- No new August 26 announcement or definitive catalyst explains the pre-market decline; the broader market is nearly flat and does not appear to be driving the move.